Literature DB >> 33624128

A tandem giant magnetoresistance assay for one-shot quantification of clinically relevant concentrations of N-terminal pro-B-type natriuretic peptide in human blood.

Fanda Meng1,2,3, Weisong Huo4, Jie Lian5, Lei Zhang4, Xizeng Shi4, Aldo Jesorka6, Yunhua Gao7,8.   

Abstract

We report a microfluidic sandwich immunoassay constructed around a dual-giant magnetoresistance (GMR) sensor array to quantify the heart failure biomarker NT-proBNP in human plasma at the clinically relevant concentration levels between 15 pg/mL and 40 ng/mL. The broad dynamic range was achieved by differential coating of two identical GMR sensors operated in tandem, and combining two standard curves. The detection limit was determined as 5 pg/mL. The assay, involving 53 plasma samples from patients with different cardiovascular diseases, was validated against the Roche Cobas e411 analyzer. The salient features of this system are its wide concentration range, low detection limit, small sample volume requirement (50 μL), and the need for a short measurement time of 15 min, making it a prospective candidate for practical use in point of care analysis.

Entities:  

Keywords:  Biosensor; GMR; Microfluidic; NT-proBNP; POCT

Year:  2021        PMID: 33624128     DOI: 10.1007/s00216-021-03227-5

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  20 in total

1.  NT-proBNP in unstable coronary artery disease--experiences from the FAST, GUSTO IV and FRISC II trials.

Authors:  Tomas Jernberg; Stefan James; Bertil Lindahl; Mats Stridsberg; Per Venge; Lars Wallentin
Journal:  Eur J Heart Fail       Date:  2004-03-15       Impact factor: 15.534

Review 2.  Recent advances in point-of-care testing for natriuretic peptides: potential impact on heart failure diagnosis and management.

Authors:  James A Iwaz; Alan S Maisel
Journal:  Expert Rev Mol Diagn       Date:  2016-03-25       Impact factor: 5.225

Review 3.  Cardiac markers and their point-of-care testing for diagnosis of acute myocardial infarction.

Authors:  Zhen Yang; Dao Min Zhou
Journal:  Clin Biochem       Date:  2006-06-07       Impact factor: 3.281

Review 4.  Point-of-care testing (POCT) and evidence-based laboratory medicine (EBLM) - does it leverage any advantage in clinical decision making?

Authors:  Christopher Florkowski; Andrew Don-Wauchope; Nuria Gimenez; Karina Rodriguez-Capote; Julien Wils; Annalise Zemlin
Journal:  Crit Rev Clin Lab Sci       Date:  2017-11-23       Impact factor: 6.250

5.  Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.

Authors:  Michael R Zile; Brian L Claggett; Margaret F Prescott; John J V McMurray; Milton Packer; Jean L Rouleau; Karl Swedberg; Akshay S Desai; Jianjian Gong; Victor C Shi; Scott D Solomon
Journal:  J Am Coll Cardiol       Date:  2016-12-06       Impact factor: 24.094

6.  Ninety-minute exclusion of acute myocardial infarction by use of quantitative point-of-care testing of myoglobin and troponin I.

Authors:  J McCord; R M Nowak; P A McCullough; C Foreback; S Borzak; G Tokarski; M C Tomlanovich; G Jacobsen; W D Weaver
Journal:  Circulation       Date:  2001-09-25       Impact factor: 29.690

7.  Heart failure.

Authors:  Henry Krum; William T Abraham
Journal:  Lancet       Date:  2009-03-14       Impact factor: 79.321

Review 8.  Biomarkers and diagnostics in heart failure.

Authors:  Hanna K Gaggin; James L Januzzi
Journal:  Biochim Biophys Acta       Date:  2013-01-09

9.  Predictive value of NT-pro BNP after acute myocardial infarction: relation with acute and chronic infarct size and myocardial function.

Authors:  Agnes Mayr; Johannes Mair; Michael Schocke; Gert Klug; Kathrin Pedarnig; Bernhard Johannes Haubner; Martha Nowosielski; Thomas Grubinger; Otmar Pachinger; Bernhard Metzler
Journal:  Int J Cardiol       Date:  2009-11-07       Impact factor: 4.164

10.  Is it safe to discharge patients from accident and emergency using a rapid point of care Triple Cardiac Marker test to rule out acute coronary syndrome in low to intermediate risk patients presenting with chest pain?

Authors:  S Rathore; P Knowles; A P S Mann; P A Dodds
Journal:  Eur J Intern Med       Date:  2008-03-14       Impact factor: 4.487

View more
  4 in total

1.  Quantitative and rapid detection of morphine and hydromorphone at the point of care by an automated giant magnetoresistive nanosensor platform.

Authors:  Dana L Cortade; Shan X Wang
Journal:  Anal Bioanal Chem       Date:  2022-08-19       Impact factor: 4.478

2.  One-Shot Full-Range Quantification of Multi-Biomarkers With Different Abundance by a Tandem Giant Magnetoresistance Assay.

Authors:  Fanda Meng; Lei Zhang; Jie Lian; Weisong Huo; Xizeng Shi; Yunhua Gao
Journal:  Front Chem       Date:  2022-05-19       Impact factor: 5.545

3.  Dynamic Range Expansion of the C-Reactive Protein Quantification with a Tandem Giant Magnetoresistance Biosensor.

Authors:  Fanda Meng; Lei Zhang; Weisong Huo; Jie Lian; Aldo Jesorka; Xizeng Shi; Yunhua Gao
Journal:  ACS Omega       Date:  2021-05-07

Review 4.  Giant Magnetoresistance Biosensors for Food Safety Applications.

Authors:  Shuang Liang; Phanatchakorn Sutham; Kai Wu; Kumar Mallikarjunan; Jian-Ping Wang
Journal:  Sensors (Basel)       Date:  2022-07-28       Impact factor: 3.847

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.